会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • SUSTAINED RELEASE OF ANTIINFECTIVES
    • 持续释放抗生素
    • US20140314835A1
    • 2014-10-23
    • US14319018
    • 2014-06-30
    • INSMED INCORPORATED
    • Lawrence T. BoniBrian S. MillerVladimir MalininXingong Li
    • A61K47/28A61K9/127A61K45/06A61K31/7036
    • A61K47/28A61K9/0078A61K9/127A61K9/1277A61K31/407A61K31/4709A61K31/496A61K31/545A61K31/7036A61K31/704A61K45/06Y02A50/473
    • Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.
    • 提供基本上不含阴离子脂质的脂质抗感染制剂,其脂质与抗感染比为约1:1至约4:1,平均平均直径小于约1μm。 还提供了制备包含输注方法的脂质抗感染制剂的方法。 还提供了脂质抗感染制剂,其中通过在线融合方法制备的脂质与药物的比例为约1:1或更低,约0.75:1或更低,或约0.50:1或更低。 本发明还涉及治疗患有肺部感染的患者的方法,其包括向患者施用治疗有效量的本发明的抗脂质抗感染药物。 本发明还涉及一种治疗患者囊性纤维化的方法,其包括向患者施用治疗有效量的本发明的抗脂质抗感染制剂。